Vivos Therapeutics (NASDAQ:VVOS) announced it has signed a US-wide distribution agreement for its oral appliances with Lincare, a leading supplier of in-home respiratory therapy products and services to about 1.8 million patients.
The company noted that the distribution agreement comes on the heels of a distribution pilot with Lincare and will allow Vivos to engage with durable medical equipment (DME) companies in the US.
Lincare will have six-month exclusivity to distribute certain Vivos devices, it added.
“This important collaboration between a national supplier of DME like Lincare and an innovative oral appliance company like Vivos will bring fresh solutions and relief to patients currently seeking alternatives,” Vivos CEO Kirk Huntsman said in a statement.
“Our pilot trial allowed both parties time to work through the program logistics, including the development of a new Vivos proprietary software to manage DME patients and scale to a national level.”
Lincare CEO Jeff Barnhard added that it was pleased to offer oral appliances as an alternative treatment to its non-compliant continuous positive airway pressure (CPAP) patients.
“Finding the best solutions for our sleep apnea patients has always been a high priority for Lincare. We look forward to working alongside Vivos-trained dentists.”
Investors welcomed the news, sending shares of Vivos 13.9% higher to US$0.32 in pre-market trade on Tuesday.
Vivos is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as mild-to-moderate obstructive sleep apnea and snoring in adults.
Contact the author at emily.jarvie@proactiveinvestors.com
Follow her on X, formerly known as Twitter, @emilyjjarvie